Navigation Links
Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
Date:9/2/2008

Mallinckrodt acknowledges validity of Purdue patents; Purdue licenses

limited sales of some generic oxycodone strengths

STAMFORD, Conn., Sept. 2 /PRNewswire/ -- Purdue Pharma L.P. of Stamford, Connecticut and Mallinckrodt Inc. of Hazelwood, Missouri have agreed to end the OxyContin(R) (oxycodone HCl controlled-release) Tablets patent infringement lawsuit between them in the United States District Court for the Southern District of New York.

According to the agreement, Mallinckrodt acknowledges the validity and enforceability of Purdue's patents and admits that marketing generic versions of OxyContin under its Abbreviated New Drug Application (ANDA) without a license from Purdue would infringe these patents. In exchange, Purdue has agreed to grant Mallinckrodt a royalty-bearing license, ending in 2009, to sell limited quantities of generic versions of 10 mg, 20 mg, 40 mg, and 80 mg extended-release oxycodone tablets.

In the most recent decision in the litigation which Purdue and Mallinckrodt have now settled, the United States District Court for the Southern District of New York rejected claims that the Purdue patents were unenforceable because of Purdue's alleged inequitable conduct in obtaining them. In an Opinion and Order dated January 7, 2008, the Court stated, "There is no evidence of deceptive intent with respect to Purdue's failure to disclose prior controlled-release formulations or its failure to disclose [a Purdue scientist's] affiliations, both of which were made in good faith."

"We are pleased to resolve the dispute with Mallinckrodt in a manner that respects our inventions," said John H. Stewart, President of Purdue Pharma, in announcing the end of the lawsuit. "We will continue to defend our inventions against infringers."

Purdue Pharma is a privately-held pharmaceutical company known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at http://www.purduepharma.com.

The professional product labeling for OxyContin(R) Tablets contains the following boxed warning:

WARNING:

OxyContin is an opioid agonist and a Schedule II controlled substance with an abuse liability similar to morphine.

Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing OxyContin in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

OxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.

OxyContin Tablets are NOT intended for use as a prn analgesic.

OxyContin 60 mg, 80 mg, and 160 mg Tablets, or a single dose greater than 40 mg, ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. A single dose greater than 40 mg, or total daily doses greater than 80 mg, may cause fatal respiratory depression when administered to patients who are not tolerant to the respiratory depressant effects of opioids.

OxyContin TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, OR CRUSHED. TAKING BROKEN, CHEWED, OR CRUSHED OxyContin TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF OXYCODONE.

Full prescribing information for OxyContin is available at http://www.purduepharma.com/PI/Prescription/Oxycontin.pdf .


'/>"/>
SOURCE Purdue Pharma L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Purdue leads center to simulate behavior of micro-electromechanical systems
2. Purdue creating wireless sensors to monitor bearings in jet engines
3. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
4. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
5. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
6. ViroPharma to Present at Three September Healthcare Conferences
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
9. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
10. Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 19, ... ... of advanced software solutions for pharmaceutical research and development (R&D), today announced ... in omic data analysis and interpretation for the rapidly evolving field of ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
Breaking Biology Technology:
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, ... global financial services provider, today announced an agreement with NuData ... biometrics, to join forces. The partnership will enable clients to ... in compliance with local data protection regulation. ... In order to provide ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
Breaking Biology News(10 mins):